Showing results (521-530 of 587) with videos related to
Sort By:
Pageof 59
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung CancerLaura Cipriani, Davide Mascolo, Stefano Scalera, et al.The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.Clinical Lung Cancer|November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 StudiesBob T Li, Leena Gandhi, Vignesh Ravichandran, et al.Pageof 59